Report      Database

    Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

    Date: 25 Aug, 2015              Type: Life Science              Pages: 87

    Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
    • Electronic Access - Single User License
      $1,290.00
    • CD-ROM Mail Delivery
      $1,390.00
    • Hard-copy Mail Delivery
      $1,440.00
    • Electronic Access - Multi User License
      $2,090.00

    Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.
     
    This is 3rd edition report on Hepatitis C Drugs Industry. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
     
    1. Hepatitis C Drugs Market & Forecast (Chapter 2)
    2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
    3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
    4. Hepatitis C Deals & Acquisitions (Chapter 5)
    5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
     
    Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
     
    1. Pegasys
    2. Pegintron
    3. Incivek
    4. Victrelis
    5. Olysio
    6. Sovaldi/Harvoni
    7. HCV Franchise
    8. Viekira Pak
     
    Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
     
    1. Drug A (Merck & Co. Inc.)
    2. Drug B (Merck & Co. Inc.)
    3. Drug C (Bristol-Myers Squibb)
     
    Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
     
    1. AbbVie
    2. Bristol-Myers Squibb (BMS)
    3. Gilead Sciences
    4. Merck & Co. Inc.
    5. Tibotec/Janssen Therapeutics
     
    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts.
     
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.  

    1. Executive Summary

    2. Hepatitis C Drugs – Market & Forecast

    3. Hepatitis C – Approved Drugs Sales & Forecast
    3.1 Pegasys Sales & Forecast
    3.2 Pegintron Sales & Forecast
    3.3 Incivek Sales
    3.4 Victrelis Sales & Forecast
    3.5 Olysio Sales & Forecast
    3.6 Sovaldi / Harvoni Sales & Forecast
    3.7 HCV Franchise Sales & Forecast
    3.8 Viekira Pak Sales & Forecast

    4. Hepatitis C - Pipeline Drugs Sales Forecast
    4.1 Drug A of (Merck & Co. Inc.)
    4.2 Drug B of (Merck & Co. Inc.)
    4.3 Drug C of (Bristol-Myers Squibb)

    5. Hepatitis C – Deals & Acquisitions

    6. Hepatitis C – Company Wise Clinical Trials Analysis
    6.1 AbbVie – Clinical Trials
    6.1.1 Phase III
    6.1.2 Phase II
    6.1.3 Phase I
    6.2 Bristol-Myers Squibb (BMS) – Clinical Trials
    6.2.1 Phase III
    6.2.2 Phase II
    6.3 Gilead Sciences – Clinical Trials
    6.3.1 Phase II
    6.4 Merck & Co. Inc. – Clinical Trials
    6.4.1 Phase IV
    6.4.2 Phase III
    6.4.3 Phase II
    6.4.4 Phase I
    6.5 Tibotec / Janssen Therapeutics – Clinical Trials
    6.5.1 Phase IV
    6.5.2 Phase III
    6.5.3 Phase II
    6.5.4 Phase I 

    List of Figures:

    Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2010 – 2014
    Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2015 – 2020
    Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2014
    Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2015 – 2020
    Figure 3 3: Global – Pegintron Sales (Million US$), 2010 – 2014
    Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2015 – 2020
    Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2014
    Figure 3 6: Global – Victrelis Sales & Forecast (Million US$), 2011 – 2015
    Figure 3 7: Global – Olysio Sales (Million US$), 2013 – 2014
    Figure 3 8: Global – Forecast for Olysio Sales (Million US$), 2015 – 2020
    Figure 3 9: Global – Sovaldi/Harvoni Sales (Million US$), 2013 – 2014
    Figure 3 10: Global – Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 – 2020
    Figure 3 11: Global – HCV Franchise Sales & Forecast (Million US$), 2014 – 2020
    Figure 3 12: Hepatitis C Drugs – Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
    Figure 3 13: Global – Viekira Pak Sales & Forecast (Million US$), 2014 – 2020

    Figure 4 1: Global – Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 – 2020
    Figure 4 2: Global – Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 – 2020
    Figure 4 3: Global – Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 – 2020

    List of Tables:

    Table 5 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012      

    • Description
      Price
    • Chapter 1 & 2     Pages : 6
      $250
    • Chapter 3     Pages : 20
      $400
    • Chapter 4     Pages : 4
      $200
    • Chapter 5     Pages : 5
      $150
    • Chapter 6     Pages : 40
      $200

    Related Products

    • Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide


      Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide
      Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, ...
      Date: 18 Jul, 2013
      Type: Life Science
      Pages: 164
      Price: $1,290.00
    • Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016


      Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
      Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of t...
      Date: 23 Jan, 2012
      Type: Drugs & Pharmaceuticals
      Pages: 72
      Price: $975.00